Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Director departure
Appointed director
|
|
SELLAS Life Sciences Group, Inc. (SLS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/13/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/01/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/17/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/16/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/16/2023 |
8-K
| Quarterly results |
| 03/16/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/10/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 03/01/2023 |
8-K
| Quarterly results |
| 02/24/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 02/24/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"EXHIBIT 1,1",
"COMMON STOCK PURCHASE WARRANT SELLAS Life Sciences Group, Inc. Warrant Shares: _______ Issue Date: February ___, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date and on or prior to 5:00 p.m. on February __, 2028 but not thereafter, to subscribe for and purchase from SELLAS Life Sciences Group, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall have the me...",
"SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, New York 10036",
"Printing and Mailing Expenses",
"Investor Contact" |
|
| 02/23/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 02/23/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/06/2023 |
8-K
| Quarterly results |
| 02/03/2023 |
4
| WOOD BARBARA A (EVP, Gen. Counsel, Corp. Sec.) has filed a Form 4 on SELLAS Life Sciences Group, Inc.|
Txns:
| Granted 20,000 shares
@ $0
Granted 80,000 options to buy
@ $3.34, valued at
$267.2k
|
|
| 02/03/2023 |
4
| Burns John Thomas (CFO) has filed a Form 4 on SELLAS Life Sciences Group, Inc.|
Txns:
| Granted 20,000 shares
@ $0
Granted 75,000 options to buy
@ $3.34, valued at
$250.5k
|
|
| 02/03/2023 |
4
| Stergiou Angelos M. (President and CEO) has filed a Form 4 on SELLAS Life Sciences Group, Inc.|
Txns:
| Granted 58,000 shares
@ $0
Granted 217,500 options to buy
@ $3.34, valued at
$726.5k
|
|
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/13/2022 |
8-K
| Quarterly results |
| 12/05/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/05/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/05/2022 |
4
| WOOD BARBARA A (EVP, Gen. Counsel, Corp. Sec.) has filed a Form 4 on SELLAS Life Sciences Group, Inc.|
Txns:
| Sold 2,153 shares
@ $2.59, valued at
$5.6k
|
|
| 11/15/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
|
|
|